370879-53-1

Usage

Uses

Used in Pharmaceutical Industry:
CIS-5-BENZYLTETRAHYDROPYRROLO[3,4-C]PYRROLE-1,3(2H,3AH)-DIONE is used as a pharmaceutical agent for its potential therapeutic effects. CIS-5-BENZYLTETRAHYDROPYRROLO[3,4-C]PYRROLE-1,3(2H,3AH)-DIONE's unique structure and biological activities make it a promising candidate for the development of new drugs targeting various medical conditions.
Used in Research and Development:
In the field of scientific research, CIS-5-BENZYLTETRAHYDROPYRROLO[3,4-C]PYRROLE-1,3(2H,3AH)-DIONE serves as a valuable compound for studying its pharmacological properties and exploring its potential applications in medicine. Researchers are investigating its interactions with biological targets and evaluating its efficacy in treating specific diseases.
Used in Drug Discovery:
CIS-5-BENZYLTETRAHYDROPYRROLO[3,4-C]PYRROLE-1,3(2H,3AH)-DIONE is utilized in drug discovery processes to identify novel therapeutic agents. Its unique chemical structure and potential biological activities make it an attractive starting point for the design and synthesis of new drugs with improved efficacy and selectivity.
Used in Chemical Synthesis:
In the chemical synthesis industry, CIS-5-BENZYLTETRAHYDROPYRROLO[3,4-C]PYRROLE-1,3(2H,3AH)-DIONE can be employed as a key intermediate or building block in the synthesis of more complex molecules with potential applications in various fields, including pharmaceuticals, materials science, and agrochemicals.

InChI:InChI=1/C13H14N2O2/c16-12-10-7-15(8-11(10)13(17)14-12)6-9-4-2-1-3-5-9/h1-5,10-11H,6-8H2,(H,14,16,17)/t10-,11+

Upstream product

• 541-59-3 maleiimide 
• 93102-05-7 N-benzyl-N-(methoxymethyl)-N-[(trimethylsilyl)methyl]amine 

Downstream Products

• 1202067-90-0 tetrahydropyrrolo[3,4-c]pyrrole-1,3-dione 
• 1202067-23-9 5-[2-(2-fluoro-4-iodophenylamino)thieno[2,3-b]pyridine-3-carbonyl]tetrahydropyrrolo[3,4-c]pyrrole-1,3-dione 
• 250275-15-1 tert-butyl (3aR,6aS)-hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate 
• 370879-56-4 (3aR,6aS)-tert-butyl 5-benzylhexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate 
• 866319-07-5 cis-perhydropyrrolo[3,4-c]pyrrole-1,3-dione 
• 172739-04-7 cis-3-benzyl-3,7-diazabicyclo[3.3.0]octane 

Relevant academic research and scientific papers

QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS

Compounds of formula (I) that are Fibroblast Growth Factor Inhibitors (FGFR) and are therefore useful for the treatment of diseases treatable by inhibition of FGFR are disclosed. Also disclosed are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS

Compounds that are Fibroblast Growth Factor Inhibitors (FGFR) and are therefore useful for the treatment of diseases treatable by inhibition of FGFR are disclosed. Also disclosed are pharmaceutical compositions containing such compounds and processes for

Selective Ligands for the Neuronal Nicotinic Receptors and Uses Thereof

The present application describes selective ligands of formula (I) for neuronal nicotinic receptors (NNRs), more specifically for the α4β2 NNR subtype, compositions thereof, and methods of using the same, wherein X, R1, X, R2, R3, L1, m, n, p, and q are defined in the specification.

Octahydropyrrolo[3,4-c]pyrrole: A diamine scaffold for construction of either α4β2 or α7-selective nicotinic acetylcholine receptor (nAChR) ligands. Substitutions that switch subtype selectivity

A series of 5-(pyridine-3-yl)octahydropyrrolo[3,4-c]pyrroles have been prepared that exhibit high affinity to α4β2 and/or α7 nicotinic acetylcholine receptors (nAChRs). Simple substitution patterns have been identified that allow construction of ligands that are highly selective for either nAChR subtype. The effects of substitution on subtype selectivity provide some insight into the differences in the ligand binding domains of the α4β2 and R7 receptors, especially in regions removed from the cation binding pocket.

Diazabicyclic central nervous system active agents

Compounds of formula I pharmaceutical compositions of these compounds, and use of said compositions to control synaptic transmission in mammals.